Repligen Co. (NASDAQ:RGEN) Shares Sold by Legato Capital Management LLC

Legato Capital Management LLC decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 31.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,940 shares of the biotechnology company’s stock after selling 3,630 shares during the period. Legato Capital Management LLC’s holdings in Repligen were worth $1,143,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Allspring Global Investments Holdings LLC boosted its holdings in Repligen by 79.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock worth $65,395,000 after buying an additional 203,011 shares in the last quarter. Louisiana State Employees Retirement System lifted its position in shares of Repligen by 0.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock valued at $2,087,000 after acquiring an additional 100 shares during the last quarter. Angeles Wealth Management LLC bought a new stake in shares of Repligen during the 4th quarter worth $220,000. Stephens Investment Management Group LLC grew its holdings in shares of Repligen by 7.4% in the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock worth $77,267,000 after acquiring an additional 37,057 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Repligen by 46.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,629 shares of the biotechnology company’s stock worth $2,679,000 after purchasing an additional 5,913 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Price Performance

NASDAQ RGEN opened at $145.72 on Thursday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $8.16 billion, a PE ratio of -393.83, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13. The company has a 50 day moving average price of $155.45 and a two-hundred day moving average price of $149.14.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same quarter in the previous year, the business earned $0.23 EPS. Repligen’s quarterly revenue was up 9.7% compared to the same quarter last year. As a group, equities analysts predict that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RGEN has been the subject of a number of recent analyst reports. Wolfe Research initiated coverage on Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Finally, TD Cowen assumed coverage on Repligen in a report on Monday. They issued a “buy” rating and a $200.00 target price for the company. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, Repligen has an average rating of “Moderate Buy” and a consensus price target of $186.00.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.